The Cost of Treating Pancreatic Cancer

Hjelmgren, Jonas; Ceberg, Jeanette; Persson, Ulf; Alvegård, Thor

doi:10.1080/02841860310000386

Cited by 18 publications

(24 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are consistent with previous studies of pancreatic cancer 7–9,41,42 and other cancers. 18,19,43 The proportion of costs attributable to inpatient care unrelated to cancer-directed procedures was highest for those diagnosed with distant disease, possibly due to extensive hospitalization over a limited time period.…”

Section: Discussionsupporting

confidence: 94%

“…18,19,43 The proportion of costs attributable to inpatient care unrelated to cancer-directed procedures was highest for those diagnosed with distant disease, possibly due to extensive hospitalization over a limited time period. 8,41,44 In addition, inpatient costs were relatively stable over time, although we did observe an increase in costs of outpatient care and physician services. In recent years, across a range of cancer types and stages of disease, treatment costs have shifted away from the inpatient setting toward outpatient care.…”

Section: Original Article 5134mentioning

confidence: 62%

See 1 more Smart Citation

Costs and trends in pancreatic cancer treatment

O'Neill

Atoria

O’Reilly

et al. 2012

Cancer

View full text Add to dashboard Cite

BACKGROUND Pancreatic cancer poses a substantial morbidity and mortality burden in the United States, and predominantly affects older adults. The objective of this study was to estimate the direct medical costs of pancreatic cancer treatment in a population-based cohort of Medicare beneficiaries, and the contribution of different treatment modalities and health care services to the total cost of care and trends in costs over time. METHODS In the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare database, pancreatic cancer patients were identified who were aged 66 years or older and who were diagnosed from 2000 to 2007. Total direct medical costs were estimated from Medicare payments overall and within categories of care. Costs attributable to pancreatic cancer were estimated by subtracting the costs of medical care in a matched cohort of cancer-free beneficiaries. RESULTS A total of 15,037 patients were identified, of whom 97% were observed from diagnosis until death. Mean total direct medical costs were $65,500. Mean total costs were greater for patients with resectable locoregional disease ($134,700) than for those with unresectable locoregional or distant disease ($65,300 and $49,000, respectively). Hospitalizations and cancer-directed procedures collectively accounted for the largest fraction of health care costs. The total cost of care appeared to increase slightly over the study period (P = .05). The mean costs attributable to pancreatic cancer were $61,700. CONCLUSIONS Despite poor prognosis and short survival, the economic burden of pancreatic cancer in the elderly is substantial. Demographic trends, greater use of targeted therapies, and possible implementation of screening strategies are likely to impact treatment patterns and costs in the future.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Original Article 5134mentioning

confidence: 62%

Costs and trends in pancreatic cancer treatment

O'Neill

Atoria

O’Reilly

et al. 2012

Cancer

View full text Add to dashboard Cite

show abstract

“…Median survival from diagnosis was reported in 12 studies [ 26 , 37 , 38 , 33 , 34 , 18 , 39 – 44 ], mainly from Nordic countries (8/12 studies), and ranged from 1 to 6.1 months, with an overall median of 4.6 (Fig. 3 ).…”

Section: Resultsmentioning

confidence: 99%

“…The two largest studies (in Norwegian and Swedish populations of 21,663 and 16,758 patients, respectively) both reported a median survival of 3 months [ 33 , 18 ]. When reported, stage at diagnosis was generally advanced, with half the studies reporting >40 % of patients with metastatic disease [ 26 , 34 , 39 – 41 , 43 ]. In general, median survival was shorter in older populations (1 to 3.2 months; median age 70–76 years) versus younger ones (5 to 6.1 months; median ages 62–67 years).…”

Section: Resultsmentioning

confidence: 99%

A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs

Carrato

Falcone

Ducreux

et al. 2015

J Gastrointest Canc

230

187

View full text Add to dashboard Cite

PurposeThe purpose of this study was to assess the overall burden of pancreatic cancer in Europe, with a focus on survival time in a real-world setting, and the overall healthy life lost to the disease.MethodsReal-world data were retrieved from peer-reviewed, observational studies identified by an electronic search. We performed two de novo analyses: a proportional shortfall analysis to quantify the proportion of healthy life lost to pancreatic cancer and an estimation of the aggregate life-years lost annually in Europe.ResultsNinety-one studies were included. The median, age-standardised incidence of pancreatic cancer per 100,000 was 7.6 in men and 4.9 in women. Overall median survival from diagnosis was 4.6 months; median survival was 2.8–5.7 months in patients with metastatic disease. The proportional shortfall analysis showed that pancreatic cancer results in a 98 % loss of healthy life, with a life expectancy at diagnosis of 4.6 months compared to 15.1 years for an age-matched healthy population. Annually, 610,000–915,000 quality-adjusted life-years (QALYs) are lost to pancreatic cancer in Europe. Patients had significantly lower scores on validated health-related quality of life instruments versus population norms.ConclusionsTo the best of our knowledge, this is the first study to systematically review real-world overall survival and patient outcomes of pancreatic cancer patients in Europe outside the context of clinical trials. Our findings confirm the poor prognosis and short survival reported by national studies. Pancreatic cancer is a substantial burden in Europe, with nearly a million aggregate life-years lost annually and almost complete loss of healthy life in affected individuals.Electronic supplementary materialThe online version of this article (doi:10.1007/s12029-015-9724-1) contains supplementary material, which is available to authorized users.

show abstract

“…In general, the costs for patients with pancreatic cancer involve diagnosis, treatment, hospitalization, and productivity loss [104,105,106]. These high costs need to be reduced and be subject to economic evaluation [107,108].…”

Section: Considerationmentioning

confidence: 99%

Familial Pancreatic Cancer

Benzel

Fendrich

2018

Oncol Res Treat

View full text Add to dashboard Cite

Familial pancreatic cancer accounts for 10% of all patients with pancreatic cancer. Because the 5-year survival rate of pancreatic cancer is only 7%, screening programs for high-risk individuals are essential and might be advantageous. Pancreatic ductal adenocarcinoma mostly shows symptoms at an advanced state and treatment is not efficient enough to cure most patients. People with hereditary tumor syndromes or their affected relatives can also be included in such screening programs. Besides the collection of data to investigate the background of the disease, these screening programs aim to diagnose and treat precursor lesions so that more dangerous, invasive lesions are prevented. These precursor lesions can be pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and mucinous cystic neoplasm. This review summarizes the latest knowledge of pancreatic screening programs, shows the procedure of pancreatic cancer screening, and gives an overview of current guidelines.

show abstract

The Cost of Treating Pancreatic Cancer

Cited by 18 publications

References 13 publications

Costs and trends in pancreatic cancer treatment

Costs and trends in pancreatic cancer treatment

A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs

Familial Pancreatic Cancer

Contact Info

Product

Resources

About